Article by Yippee-Ki-Yay

SKAN Group analysis: the Swiss gem that is switching to ‘cash machine’ mode

Buy signal | Private publication | 22 Dec 2025

SKAN Group AG: A Swiss gem in the healthcare sector?

Hello, daring investors and market enthusiasts! Today, we're diving into the figures of SKAN Group AG, a Swiss publicly traded company operating in the healthcare sector (more specifically in sterilisation and asepsis solutions, a highly promising field in the post-pandemic period). We'll be analysing its financial health and forecasts, and we'll even venture to do a little valuation calculation to see if this stock deserves a place in your portfolio. Hold on tight, we're talking business, cash and growth potential!

SKAN Group AG identity card

SKAN Group AG is a provider of isolation and sterilisation system solutions for the pharmaceutical and biotechnology industries. Based in Switzerland, it operates internationally and benefits from strong structural demand thanks to increasingly stringent health standards. Its shares are trading at around CHF 49.36 on the stock market. The company already has a solid market capitalisation and is enjoying steady revenue growth.

Financial quality analysis (out of 5)

A brief internal assessment to evaluate SKAN's robustness. Each criterion is rated out of 5, with a brief comment to justify the rating.

📈 Turnover – Rating: 4/5

The Board of Directors has made steady progress:

  • 2021: 234.26 million Swiss francs
  • 2024: 361.29 million Swiss francs

This is a nice upward curve, supported by demand for pharmaceutical equipment. The forecast for 2026 is even higher, at CHF 450.98 million. We deduct one point because growth is not explosive, but it is stable and predictable.

💰 Net result – Rating: 4/5

Net income follows the trend:

  • 2021: 10.61 million Swiss francs
  • 2024: 38.80 million Swiss francs

A more than 3.5-fold increase in four years is impressive. The net margin is improving, a sign that profitability is on track. The forecasts for 2026 (CHF 44.49 million) and 2027 (CHF 88.71 million) are downright optimistic.

📊 Return on equity (ROE) – Rating: 3/5

ROE is somewhat volatile:

  • 2024: 21.24% (excellent)
  • Forecast for 2025: 5.54% (significant decrease)
  • Then rises to 10-13% in subsequent years.

The volatility of ROE may indicate heavy ongoing investment (high capex). This is good for future growth, but it drags the score down in the short term.

🚀 Market performance & sentiment – Rating: 4/5

The share price rose from an EPS of CHF 0.84 in 2021 to CHF 1.72 in 2024. EPS forecasts of CHF 1.98 (2026) and CHF 2.62 (2027) suggest analyst confidence. The current P/E ratio (68.11) is high, but is expected to normalise to 48.64 within 12 months according to forecasts. The healthcare sector remains defensive and promising.

🧮 Overall average: 4/5

SKAN has a solid profile, steady growth, very low debt, but profitability needs to be monitored. It is a high-quality, well-managed company with potential for stock market appreciation.

Forecasts for the Coming Years

The forecasts for SKAN Group AG are optimistic. Here are some estimates for the years 2025 to 2029:

  • 2025: Revenue of CHF 358.799 million, net income of CHF 22.793 million, EPS of CHF 1.007.
  • 2026: Revenue of CHF 450.985 million, net income of CHF 44.494 million, EPS of CHF 1.978.
  • 2027: Revenue of CHF 540.098 million, net income of CHF 58.706 million, EPS of CHF 2.619.
  • 2028: Revenue of CHF 699.35 million, net income of CHF 91.25 million, EPS of CHF 3.965.
  • 2029: Revenue of CHF 681.5 million, net income of CHF 52.6 million, EPS of CHF 3.4.

The trajectory is clear: revenue growth, improved profitability, and transformation into a net cash positive company. This is exactly the kind of scenario that appeals to medium-term investors.

Estimated share value in 2026 and 2027

We will use a simplified target PER valuation model:

  • PER sectoriel moyen pour les équipementiers santé : autour de 25-30x.
  • EPS forecast for 2026: CHF 1.98 → Estimated share price = 1.98 x 28 = CHF 55.44.
  • EPS forecast for 2027: CHF 2.62 → Estimated share price = 2.62 x 28 = CHF 73.36.

Based on a current price of CHF 49.36, this represents potential growth of +12% in 2026 and +48% in 2027. Please note that this assumes that the market will validate the growth and that the forecasts will be met.

Conclusion: Is SKAN a good candidate for your portfolio?

SKAN Group AG is a bit like the serious student in the healthcare class: it is growing steadily, has no debt and promises to deliver more tomorrow. The forecasts are optimistic, and its valuation could climb if the results follow suit.

Strengths:

  • Growth in turnover and net profit
  • Virtually zero debt by 2027
  • Rising dividends
  • Promising and defensive sector

Points to watch:

  • High P/E ratio today
  • Fluctuating ROE
  • Significant capex (but justified by growth)

Verdict: If you are looking for a solid, growing company with a rock-solid balance sheet, SKAN is definitely worth considering. In a diversified portfolio, it can provide stability and potential for capital gains.

And don't forget: investing is like preparing a good Swiss dish – it takes time, patience and high-quality ingredients. SKAN is one of those ingredients.

Disclaimer: This is not investment advice, but an educational analysis. Do your own research (or call your favourite financial guru) before investing.

  • Signal : Buy
  • Budget/Investment : High
  • Reinforcement required : No
  • Exposure : Low
  • Horizon : 1 to 2 years
  • Potential profitability : +12% to +48%
  • Ref. ISIN code : CH0013396012
  • Article updated on 20/08/2026: All shares sold at CHF 65. An impressive return of 31.7% in just 9 monthss 😄​.